Our radiogenomics profiling reveals that immune cell markers such as TAM markers have significant correlations with nCBV and ADC values, and CD49d expression level correlated with ADC can be considered as a candidate biomarker to predict progression of GBM patients. This evidence concerns the gene ITGA4 and glioblastoma.